Drug Trial Radar · NCT06841315
A Varegacestat Hepatic Impairment Study
Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Mar 7, 2025
Primary completion
Nov 5, 2025
Study completion Mar 6, 2026
Sponsor
- Lead sponsor
- Immunome, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 84 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.
Conditions
- Healthy Volunteer
- Hepatic Impairment (HI)
Interventions
varegacestatDrug
experimental intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.Time frame: Up to 4 weeks
- PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.Time frame: Up to 4 weeks
- PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.Time frame: Up to 4 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Orlando Clinical Research Center
Orlando, Florida
The Texas Liver Institute
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.